ArticleBMC nephrology2025
Evaluation of serum miR-122-5p, miR-486-5p, miR-21-5p, and their interplay with inflammatory markers in diabetic nephropathy: a case control study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Urinary Extracellular Vesicle-Derived miRNAs as Regulators and Biomarkers in Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- Circulating Liver-Enriched miR-122 in COVID-19 Patients: A Longitudinal Real-Life Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of diabetic kidney disease (DKD), a major consequence of type 2 diabetes mellitus (T2DM), is impacted by hereditary factors, immunological dysregulation, and inflammation. Inflammatory indicators and circulating microRNAs (miRNAs) can be stable and used as diagnostic biomarkers. The objective of this study was to assess whether serum miRNA-122-5p, miRNA-486-5p, and miRNA-21-5p can serve as non-invasive diagnostic biomarkers for DKD by comparing their levels in T2DM patients with and without DKD against healthy controls, and by examining their correlations with inflammatory markers (IL-6, TNF-α, and hsCRP). Finally, their role in DKD pathogenesis was also investigated through their possible target genes using a bioinformatic analysis. A total of 1350 individuals were enrolled: 450 T2DM with DKD, 450 with T2DM without DKD, and 450 healthy controls. We used qRT-PCR to quantify miRNA expression, ELISA to assess IL-6 and TNF-α, and an immunoturbidimetric technique to detect hsCRP. We found that miRNA-122-5p and miRNA-21-5p levels were substantially elevated in DKD patients and positively correlated with hsCRP and TNF-α; miRNA-21-5p also correlated with IL-6. Conversely, miRNA-486-5p expression was markedly reduced in the DKD group and showed no correlation with inflammatory markers. Enrichment analysis revealed involvement in TNF signaling, insulin resistance, and growth hormone pathways. Their differential expression in DKD may support the utility of miRNA-122-5p, miRNA-21-5p, and miRNA-486-5p expression as potential biomarkers for DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.